Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease

NCT01354691 is registered in ClinicalTrials.gov with Avraham Pharmaceuticals Ltd as lead sponsor.

NCT NCT01354691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01354691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease
Lead sponsor
Avraham Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
March 31, 2013
Enrollment
200 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, cognitive impairment, dementia, memory loss